June 07, 2018
Rose
Stakeholders across healthcare are beginning to weigh the benefits and challenges digital therapeutics could bring to their businesses, and pharma is no exception. During an afternoon roundtable session held yesterday at BIO 2018 in Boston, a panel of digital medicine and pharmaceutical representatives discussed the impact that these novel medicines has had, and could have, on drugmakers, regulators, and those prescribing the medications.
from MobiHealthNews https://ift.tt/2HrewL3
June 07, 2018
Rose
MobiHealthNews
No comments
Related Posts:
FDA makes premarket exemption official for genetic risk assessments- Insulet gets FDA nod to commercialize Omnipod Dash Insulin Management System
- Automated workouts, activity competitions, screen time reduction tools debut at Apple's WWDC
- Study: Heart patients monitored with Fitbits keep up with device use
- Teladoc acquires virtual health company Advance Medical
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment